Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 8 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
Early P 1 (4)
P 1 (2)
P 2 (1)

Trial Status

Unknown5
Recruiting3

Clinical Trials (8)

Showing 8 of 8 trials
NCT06378190Phase 1RecruitingPrimary

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT04300998Recruiting

Study of CAR-T Therapy in Older Patients

NCT06158386Phase 2Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

NCT05003141Phase 1Unknown

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

NCT03690310Early Phase 1UnknownPrimary

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03824964Early Phase 1UnknownPrimary

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03824951Early Phase 1UnknownPrimary

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

NCT03692767Early Phase 1UnknownPrimary

Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Showing all 8 trials

Research Network

Activity Timeline